Attenuation of MPTP/MPP+ toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin

Neuroscience

Volumn 236, Issue , 2013, Pages 373-393

  Gao, H L ^a,c   Li, C ^a,d   Nabeka, H ^a   Shimokawa, T ^a   Saito, S ^b   Wang, Z Y ^c   Cao, Y M ^d   Matsuda, S ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c NORTHEASTERN UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 1 methyl 4 phenylpyridinium ion; Dopaminergic neurons; Parkinson's disease; Prosaposin derived 18 mer peptide; SH SY5Y

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 18 MER PEPTIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; PEPTIDE; PROSAPOSIN; STRESS ACTIVATED PROTEIN KINASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PSAP PROTEIN, MOUSE; SPHINGOLIPID ACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; C57BL 6 MOUSE; CELL COUNTING; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL LINE; DRUG EFFECT; PARKINSONISM;

ANIMALS; APOPTOSIS; CELL LINE; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PEPTIDES; SAPOSINS;

EID: 84883005595     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.01.007     Document Type: Article

References (88)

1. Beal M.F. Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol 1992, 2:657-662.
2. Bjorklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
3. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
4. Borsello T., Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007, 13:1875-1886.
5. Cabral A.L., Hays A.N., Housley P.R., Brentani M.M., Martins V.R. Repression of glucocorticoid receptor gene transcription by c-Jun. Mol Cell Endocrinol 2001, 175:67-79.
6. Campana W.M., Hiraiwa M., O'Brien J.S. Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 1998, 12:307-314.
7. Cheng B., Yang X., Hou Z., Lin X., Meng H., Li Z., Liu S. D-beta-hydroxybutyrate inhibits the apoptosis of PC12 cells induced by 6-OHDA in relation to up-regulating the ratio of Bcl-2/Bax mRNA. Auton Neurosci 2007, 134:38-44.
8. Choi W.S., Yoon S.Y., Oh T.H., Choi E.J., O'Malley K.L., Oh Y.J. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 1999, 57:86-94.
9. Chun H.S., Gibson G.E., DeGiorgio L.A., Zhang H., Kidd V.J., Son J.H. Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. J Neurochem 2001, 76:1010-1021.
10. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
11. Crompton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol 2000, 12:414-419.
12. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5:137-143.
13. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
14. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
15. Dodel R.C., Du Y., Bales K.R., Ling Z.D., Carvey P.M., Paul S.M. Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience 1998, 86:701-707.
16. Furst W., Machleidt W., Sandhoff K. The precursor of sulfatide activator protein is processed to three different proteins. Biol Chem Hoppe Seyler 1988, 369:317-328.
17. Gao H.L., Zheng W., Xin N., Chi Z.H., Wang Z.Y., Chen J. Zinc deficiency reduces neurogenesis accompanied by neuronal apoptosis through caspase-dependent and -independent signaling pathways. Neurotox Res 2009, 16:416-425.
18. Gearan T., Castillo O.A., Schwarzschild M.A. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism Relat Disord 2001, 8:19-22.
19. Giulian D., Woodward J., Young D.G., Krebs J.F., Lachman L.B. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988, 8:2485-2490.
20. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 2000, 97:2875-2880.
21. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., Agid Y., Hirsch E.C. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. J Neurochem 2001, 76:1785-1793.
22. Hausmann R., Riess R., Fieguth A., Betz P. Immunohistochemical investigations on the course of astroglial GFAP expression following human brain injury. Int J Legal Med 2000, 113:70-75.
23. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
24. Hiesberger T., Huttler S., Rohlmann A., Schneider W., Sandhoff K., Herz J. Cellular uptake of saposin (SAP) precursor and lysosomal delivery by the low density lipoprotein receptor-related protein (LRP). EMBO J 1998, 17:4617-4625.
25. Himeda T., Watanabe Y., Tounai H., Hayakawa N., Kato H., Araki T. Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice. J Neural Transm 2006, 113:1887-1894.
26. Hineno T., Sano A., Kondoh K., Ueno S., Kakimoto Y., Yoshida K. Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 1991, 176:668-674.
27. Hiraiwa M., Soeda S., Kishimoto Y., O'Brien J.S. Binding and transport of gangliosides by prosaposin. Proc Natl Acad Sci U S A 1992, 89:11254-11258.
28. Hiraiwa M., Yamauchi T., Tsuji S., Nishizawa M., Miyatake T., Oyanagi K., Ikuta F., Uda Y. Activation of human lysosomal sialidase. J Biochem 1993, 114:901-905.
29. Hiraiwa M., Campana W.M., Martin B.M., O'Brien J.S. Prosaposin receptor: evidence for a G-protein-associated receptor. Biochem Biophys Res Commun 1997, 240:415-418.
30. Hiraiwa M., Taylor E.M., Campana W.M., Darin S.J., O'Brien J.S. Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Natl Acad Sci U S A 1997, 94:4778-4781.
31. Hirsch E.C., Hunot S., Damier P., Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann Neurol 1998, 44:S115-S120.
32. Hozumi I., Hiraiwa M., Inuzuka T., Yoneoka Y., Akiyama K., Tanaka R., Kikugawa K., Nakano R., Tsuji S., O'Brien J.S. Administration of prosaposin ameliorates spatial learning disturbance and reduces cavity formation following stab wounds in rat brain. Neurosci Lett 1999, 267:73-76.
33. Igase K., Tanaka J., Kumon Y., Zhang B., Sadamoto Y., Maeda N., Sakaki S., Sakanaka M. An 18-mer peptide fragment of prosaposin ameliorates place navigation disability, cortical infarction, and retrograde thalamic degeneration in rats with focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:298-306.
34. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
35. Junn E., Mouradian M.M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases. J Neurochem 2001, 78:374-383.
36. Kanthasamy A.G., Anantharam V., Zhang D., Latchoumycandane C., Jin H., Kaul S., Kanthasamy A. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCdelta) protects against dopaminergic neuronal degeneration in Parkinson's disease models. Free Radic Biol Med 2006, 41:1578-1589.
37. Kim H.E., Yoon S.Y., Lee J.E., Choi W.S., Jin B.K., Oh T.H., Markelonis G.J., Chun S.Y., Oh Y.J. MPP(+) downregulates mitochondrially encoded gene transcripts and their activities in dopaminergic neuronal cells: protective role of Bcl-2. Biochem Biophys Res Commun 2001, 286:659-665.
38. Kim I.S., Koppula S., Kim B.W., Song M.D., Jung J.Y., Lee G., Lee H.S., Choi D.K. A novel synthetic compound PHID (8-phenyl-6a, 7, 8, 9, 9a, 10-hexahydro-6H-isoindolo [5, 6-g] quinoxaline-7, 9-dione) protects SH-SY5Y cells against MPP(+)-induced cytotoxicity through inhibition of reactive oxygen species generation and JNK signaling. Eur J Pharmacol 2011, 650:48-57.
39. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998, 39:167-180.
40. Kotani Y., Matsuda S., Sakanaka M., Kondoh K., Ueno S., Sano A. Prosaposin facilitates sciatic nerve regeneration in vivo. J Neurochem 1996, 66:2019-2025.
41. Kotani Y., Matsuda S., Wen T.C., Sakanaka M., Tanaka J., Maeda N., Kondoh K., Ueno S., Sano A. A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo. J Neurochem 1996, 66:2197-2200.
42. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
43. Kuwana T., Newmeyer D.D. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 2003, 15:691-699.
44. Lee D.H., Szczepanski M., Lee Y.J. Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol 2008, 75:2345-2355.
45. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
46. Liu J., Wang C.Y., O'Brien J.S. Prosaptide D5, a retro-inverso 11-mer peptidomimetic, rescued dopaminergic neurons in a model of Parkinson's disease. FASEB J 2001, 15:1080-1082.
47. Matsuda W., Furuta T., Nakamura K.C., Hioki H., Fujiyama F., Arai R., Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 2009, 29:444-453.
48. Mazumder S., Plesca D., Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol 2008, 414:13-21.
49. Mielke K., Herdegen T. JNK and p38 stresskinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000, 61:45-60.
50. Misasi R., Sorice M., Di Marzio L., Campana W.M., Molinari S., Cifone M.G., Pavan A., Pontieri G.M., O'Brien J.S. Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase. FASEB J 2001, 15:467-474.
51. Misasi R., Garofalo T., Di Marzio L., Mattei V., Gizzi C., Hiraiwa M., Pavan A., Grazia Cifone M., Sorice M. Prosaposin: a new player in cell death prevention of U937 monocytic cells. Exp Cell Res 2004, 298:38-47.
52. Mizuno Y., Mochizuki H., Sugita Y., Goto K. Apoptosis in neurodegenerative disorders. Intern Med 1998, 37:192-193.
53. Morita F., Wen T.C., Tanaka J., Hata R., Desaki J., Sato K., Nakata K., Ma Y.J., Sakanaka M. Protective effect of a prosaposin-derived, 18-mer peptide on slowly progressive neuronal degeneration after brief ischemia. J Cereb Blood Flow Metab 2001, 21:1295-1302.
54. Newman M., Tucker B., Nornes S., Ward A., Lardelli M. Altering presenilin gene activity in zebrafish embryos causes changes in expression of genes with potential involvement in Alzheimer's disease pathogenesis. J Alzheimers Dis 2009, 16:133-147.
55. Nylen K., Ost M., Csajbok L.Z., Nilsson I., Blennow K., Nellgard B., Rosengren L. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 2006, 240:85-91.
56. O'Brien J.S., Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991, 5:301-308.
57. O'Brien J.S., Carson G.S., Seo H.C., Hiraiwa M., Kishimoto Y. Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci U S A 1994, 91:9593-9596.
58. O'Brien J.S., Carson G.S., Seo H.C., Hiraiwa M., Weiler S., Tomich J.M., Barranger J.A., Kahn M., Azuma N., Kishimoto Y. Identification of the neurotrophic factor sequence of prosaposin. FASEB J 1995, 9:681-685.
59. Oyarce A.M., Fleming P.J. Multiple forms of human dopamine beta-hydroxylase in SH-SY5Y neuroblastoma cells. Arch Biochem Biophys 1991, 290:503-510.
60. Pan J., Zhao Y.X., Wang Z.Q., Jin L., Sun Z.K., Chen S.D. Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci Lett 2007, 428:82-87.
61. Pan J., Qian J., Zhang Y., Ma J., Wang G., Xiao Q., Chen S., Ding J. Small peptide inhibitor of JNKs protects against MPTP-induced nigral dopaminergic injury via inhibiting the JNK-signaling pathway. Lab Invest 2010, 90:156-167.
62. Pelinka L.E., Kroepfl A., Leixnering M., Buchinger W., Raabe A., Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004, 21:1553-1561.
63. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 2000, 16:135-142.
64. Qi X., Qin W., Sun Y., Kondoh K., Grabowski G.A. Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions. J Biol Chem 1996, 271:6874-6880.
65. Rawal N., Parish C., Castelo-Branco G., Arenas E. Inhibition of JNK increases survival of transplanted dopamine neurons in Parkinsonian rats. Cell Death Differ 2007, 14:381-383.
66. Rideout H.J., Stefanis L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol Histopathol 2001, 16:895-908.
67. Rorman E.G., Grabowski G.A. Molecular cloning of a human co-beta-glucosidase cDNA: evidence that four sphingolipid hydrolase activator proteins are encoded by single genes in humans and rats. Genomics 1989, 5:486-492.
68. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
69. Sano A., Matsuda S., Wen T.C., Kotani Y., Kondoh K., Ueno S., Kakimoto Y., Yoshimura H., Sakanaka M. Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem Biophys Res Commun 1994, 204:994-1000.
70. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999, 288:421-427.
71. Saporito M.S., Thomas B.A., Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000, 75:1200-1208.
72. Sikora J., Harzer K., Elleder M. Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin. Acta Neuropathol 2007, 113:163-175.
73. Song B., Xie B., Wang C., Li M. Caspase-3 is a target gene of c-Jun:ATF2 heterodimers during apoptosis induced by activity deprivation in cerebellar granule neurons. Neurosci Lett 2011, 505:76-81.
74. Sortwell C.E., Daley B.F., Pitzer M.R., McGuire S.O., Sladek J.R., Collier T.J. Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death. J Comp Neurol 2000, 426:143-153.
75. Sun Y.N., Luo J.Y., Rao Z.R., Lan L., Duan L. GFAP and Fos immunoreactivity in lumbo-sacral spinal cord and medulla oblongata after chronic colonic inflammation in rats. World J Gastroenterol 2005, 11:4827-4832.
76. Takahashi T., Deng Y., Maruyama W., Dostert P., Kawai M., Naoi M. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J Neural Transm Gen Sect 1994, 98:107-118.
77. Tatton W.G., Chalmers-Redman R., Brown D., Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003, 53(Suppl. 3):S61-S70. [discussion S70-62].
78. Taylor E.M., Otero D.A., Banks W.A., O'Brien J.S. Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration. J Pharmacol Exp Ther 2000, 293:403-409.
79. Teismann P., Tieu K., Cohen O., Choi D.K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003, 18:121-129.
80. Teng X., Sakai T., Liu L., Sakai R., Kaji R., Fukui K. Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in nucling-deficient mice via suppression of the apoptosome pathway. J Neurochem 2006, 97:1126-1135.
81. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science 1998, 281:1312-1316.
82. Tsuboi K., Hiraiwa M., O'Brien J.S. Prosaposin prevents programmed cell death of rat cerebellar granule neurons in culture. Brain Res Dev Brain Res 1998, 110:249-255.
83. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 1971, 367:49-68.
84. Van Eldik L.J., Ehrenfried B., Jensen R.A. Production and characterization of monoclonal antibodies with specificity for the S100 beta polypeptide of brain S100 fractions. Proc Natl Acad Sci U S A 1984, 81:6034-6038.
85. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., Przedborski S. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001, 14:483-489.
86. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001, 21:9519-9528.
87. Yamada M., Kida K., Amutuhaire W., Ichinose F., Kaneki M. Gene disruption of caspase-3 prevents MPTP-induced Parkinson's disease in mice. Biochem Biophys Res Commun 2010, 402:312-318.
88. Yokoyama H., Uchida H., Kuroiwa H., Kasahara J., Araki T. Role of glial cells in neurotoxin-induced animal models of Parkinson's disease. Neurol Sci 2011, 32:1-7.